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ABSTRACT 
Background    
Evaluation of health-related quality of life (HRQL) is important in improving the quality of patient 
care. 
Methods 
The HeartQoL Project, with cross-sectional and longitudinal phases, was designed to develop a 
core ischemic heart disease (IHD) specific HRQL questionnaire, to be called the HeartQoL, for 
patients with angina, myocardial infarction (MI), or ischemic heart failure.  Patients completed a 
battery of questionnaires and Mokken scaling analysis was used to identify items in the HeartQoL 
questionnaire. 
Results 
We enrolled 6,384 patients (angina, n=2,111, 33.1%; MI, n=2,351, 36.8%; HF, n=1,922, 30.1%) 
across 22 countries and 15 languages.  The HeartQoL questionnaire comprises 14-items with 10-
item physical and 4-item emotional subscales which are scored from 0 (poor HRQL) to 3 (better 
HRQL) with a global score if needed.  The mean baseline HeartQoL global score was 2.2 (±0.5) in 
the total group and was different (p<0.001) by diagnosis (MI, 2.4 ±0.5; angina, 2.2 ±0.6; and heart 
failure, 2.1 ±0.6).   
Conclusion 
The HeartQoL questionnaire, with global and subscale scores, has the potential to allow clinicians 
and researchers to a) assess baseline HRQL, b) make between-diagnosis comparisons of HRQL, 
and c) evaluate change in HRQL in patients with angina, MI, or heart failure with a single IHD-
specific HRQL instrument. 
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INTRODUCTION 
 As one means to improve the quality of health care, the Institute of Medicine has 
emphasized the need for more patient-centered care 1.  Both the European Medicines Agency 2 
and the US Food and Drug Administration 3 have defined evaluations or reports of a patient’s 
health condition that come directly from the patient, such as health-related quality of life (HRQL), as 
patient-reported outcomes.  Patient-reported outcomes are valuable in national and international 
clinical and research studies for assessing achievement of health goals, assessing health 
disparities between population segments, evaluating health care intervention effectiveness, and 
making between-diagnosis treatment comparisons.  Specific HRQL questionnaires are designed 
for patients with either a specific disease or a specific diagnosis within a given disease 4.  However, 
this precludes between-diagnosis HRQL outcome comparisons.  Core disease-specific HRQL 
questionnaires provide a solution to this limitation; for example, between-diagnosis HRQL 
comparisons have been possible for two decades in patients with different cancer diagnoses 5, 6. 
 Ischaemic heart disease (IHD) accounts for approximately 15.4% of all deaths in Europe 7 
and 15.8% in the USA 8.  Patients with IHD, specifically angina, myocardial infarction (MI), and 
ischemic heart failure, present on a continuum of disease.  With a wide range of health status 
deficits, IHD treatment and therapeutic goals include reduced mortality and an enhanced quality of 
the longer life.  The National Heart, Lung and Blood Institute has stressed the importance of 
patient-reported outcomes in clinical care and relevant clinical trials for patients with IHD 9.  While 
valid and reliable IHD diagnosis-specific health status and HRQL tools are available for patients 
with angina, MI, and heart failure, no valid core IHD-specific HRQL instrument was available at the 
time the present project was initiated.   
 The HeartQoL Project was designed to develop and validate a core IHD-specific HRQL 
instrument for making between-diagnosis comparisons following interventions such as 
revascularization or cardiac rehabilitation that are routinely used in more than one IHD diagnosis.  
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The purpose of this paper is to describe the development of a core IHD-specific HRQL 
questionnaire, called the HeartQoL questionnaire, with psychometric properties described in a 
following paper. 
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METHODS 
 The HeartQoL Project was conducted between 2002 and 2011 in five regions (Eastern, 
Northern, Southern, and Western European regions and an English-speaking region) with a total of 
22 countries where 15 languages are spoken: Danish, Dutch, English (Australia, Canada, Ireland, 
United Kingdom, and the United States of America), French, Flemish, German (Austria, Germany, 
and Switzerland), Hungarian, Italian, Norwegian, Polish, Portuguese, Russian, Spanish (Cuba and 
Spain), Swedish, and Ukrainian 10.  Each of the sites (n=54) received local Ethics Committee or 
Institutional Review Board approval.   
 The study was conducted in two phases: 1) a cross-sectional survey phase with three 
validated IHD-specific HRQL questionnaires to identify items for inclusion in the HeartQoL 
questionnaire and described in this manuscript; 2) a second phase to test the questionnaire’s 
psychometric properties (described in a separate manuscript 11).   
 
Patients 
 The target in the cross-sectional study was to enroll at least 315 patients (105 with angina, 105 
with MI and 105 with heart failure) speaking each of 15 languages, i.e., a sample size of at least 4,725 
patients 10.  Physicians referred patients if they met the following eligibility criteria: 
a. Experienced a documented MI between 1-6 months previously; or 
b. Currently treated for angina (Canadian Cardiovascular Society class II, III or IV) with an objective 
measure of IHD (previous MI, exercise testing, echocardiogram, nuclear imaging or angiography); or 
c. Currently treated for ischaemic heart failure (New York Heart Association Class II, III, or IV) with 
evidence of left ventricular dysfunction (ejection fraction <40% by invasive or non-invasive testing) and 
an objective measure of IHD (previous MI, exercise testing, echocardiogram, nuclear imaging or 
angiography), and 
d.  Were ≥18 years old and considered by the referring physician to 1) be able to complete the self-
administered battery of HRQL instruments in the particular language, 2) not have serious 
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psychiatric disorder, and 3) not be a current substance abuser. 
 
Patient-reported outcome assessment 
 The referring clinician identified their patient’s clinical characteristics.  All patients completed a 
battery of patient-reported questionnaires.  This included a sociodemographic questionnaire, the Short-
Form 36 (SF-36) 12, 13, the Hospital Anxiety and Depression Scale (HADS) 14, 15, and three validated 
IHD-specific questionnaires selected as the foundation of to-be-developed HeartQoL questionnaire, 
the Seattle Angina Questionnaire (SAQ) 16, 17, the MacNew Heart Disease Health-related Quality of Life 
Questionnaire (MacNew) 18, 19, and the Minnesota Living With Heart Failure (MLHF) Questionnaire 20, 
21
.  The SAQ and MLHF diagnosis-specific cues (“due to chest pain, chest tightness, or angina …” and 
“how your heart failure …”, respectively) were both modified, with author permission, to “how your 
heart problem …”.  The MacNew timeframe was modified, also with permission, from “2 weeks” to “4 
weeks” to complement the timeframe used in the SAQ and MLHF.  Each questionnaire was either a) 
available in one of the 15 different languages or b) when language-specific translations were not 
available, accepted linguistic translation techniques such as forward-backward translation were used to 
translate the questionnaires 22. Two independent translators, one a health care professional and the 
other a non-health care person and fluent in each language and English, were used to develop 
necessary questionnaires. 
 
Instrument development and item reduction 
 Only the SAQ, MacNew, and MLHF items designated as physical, emotional, or social 
domain items were considered for the candidate pool of items as they are central to the 
assessment of HRQL 4.  The item reduction process consisted of two stages, first ranking the 
candidate pool items using the clinical impact method 23 and then using Mokken scaling to derive 
scales 24, 25.  
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1. Clinical impact method 
 The clinical impact method 23 asks patients to identify symptoms, activity limitations, and 
feelings that bother them in their everyday lives with the clinical impact score the product of the 
proportion bothered by an item and the “bothersomeness” score for that item on a scale from 1 to 5 
(‘little’ to ‘very’ bothered).  If a patient had responded affirmatively to an item but had given no 
“bothersomeness” score, it was imputed conservatively as follows.  Item scores ranging from “little 
to very bothered” on the original questionnaire were given a “bothersomeness” score = 1.  If the 
“bothersomeness” score was missing and the patient’s response on the original questionnaire was 
“not bothered”, those items were given a score = 0.  Items with scores ≥ 1.00 were included in the 
candidate pool of items for Mokken scaling.  
2. Mokken scaling 
 Mokken scale analysis, a hierarchical scaling method similar to Guttman scaling, 1) 
examines items in the candidate item pool for an underlying latent attribute represented by a set of 
items, 2) orders these items by degree of difficulty, and 3) uses an iterative selection procedure to 
form scales 24, 25.  Loevinger's H-coefficients measure the relationship between the numbers of 
Guttman observed errors and errors expected by chance.  By convention, strong Mokken scales 
are indicated by H-coefficients ≥0.5, 0.49 to 0.40 for moderate, and 0.39 to 0.30 for weak scales  24, 
25
.  Item and subscale thresholds of H ≥0.5 were set; both subscale and global scale H-values were 
determined.  
3. Formatting the HeartQoL questionnaire 
The HeartQoL items are introduced with the following preamble:  “We would like to know how your 
heart problem has bothered you and how you have been feeling during the last 4 weeks”.  The 
HeartQoL response options were determined with item characteristic curve modeling 26 with scores 
ranging from 0 to 3, higher scores indicating better HRQL. 
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RESULTS 
International cohort (Table 1) 
 A cohort of 6,384 patients, living in 5 different geographical regions (22 countries with 54 
sites in total) and speaking one of 15 languages, was enrolled in the HeartQoL Project; Eastern 
Europe (n=1,307 patients), Northern Europe (n=1,022 patients), Southern Europe (n=1,132 
patients), Northern Europe (n=1,449 patients), and an English-speaking region (n=1,474 patients).  
Patients were referred with a diagnosis of angina (n=2,110; 33%), MI (n=2,350; 37%), or heart 
failure (n=1,920; 30%) meeting the project target of enrolling approximately equal proportions in 
each diagnosis. 
Self-report sociodemographic and risk factors (Table 2)  
 Women made up 25% (n=1,694) of the cohort and the mean age in the total group was 
62.5 years (SD= 11.3).  The oldest patients were those with heart failure.  Patients with angina 
were significantly less likely to be men or to smoke but more likely to report hypertension or high 
cholesterol and have a higher BMI than either patients with MI or patients with HF.  Patients with MI 
were significantly more likely to be younger, to report being diabetic, and less likely to be inactive 
than patients with either angina or HF. 
Health status, anxiety and depression (Table 2) 
a. SF-36:   
 The mean physical and mental component summary (PCS and MCS, respectively) scores 
were below the population norm of 50 with lower PCS than MCS scores in all cases.  Patients with 
MI had significantly higher PCS scores than patients with angina who had higher scores than 
patients with heart failure.  There were no significant between-diagnosis MCS score differences. 
b. HADS:   
 Patients with MI had significantly lower anxiety and depression scores than patients with 
either angina or heart failure and were also least likely to have depression scores >7 (19%) 
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although most likely to report anxiety scores >7 (39%).  Patients with heart failure had lower 
anxiety scores than patients with angina while the opposite was true for depression.   
Clinical Impact Method (Table 3) 
 A candidate pool of 26 items (physical, n= 14; emotional, n= 8; social, n= 4; SAQ, n= 5; 
MacNew, n= 13; MLHF, n= 8) with clinical impact scores ≥ 1.0 was identified for the Mokken 
scaling analysis. 
a. SAQ 
 Two of the 9 eligible SAQ items, items #9 (strenuous sports) and #7 (running or jogging), 
were considered inappropriate for most patients with IHD.  Four items had clinical impact scores ≥ 
1.0 and, to capture a full range of physical activities, we included item #2 (‘walk indoors on level’; 
clinical impact score = 0.26) in the candidate pool for Mokken analysis.   
b. MacNew 
 Sixteen of the 27 eligible MacNew items had clinical impact scores ≥ 1.0.  Items #4 (‘down 
in the dumps’), #6 (‘worn out’), and #9 (‘short of breath’) had lower scores than similar MLHF items 
(#21, #13, and #12) and were excluded from the candidate pool for Mokken analysis. 
c. MLHF 
 Nine of the 13 eligible MHLF items had a score ≥ 1.0.  Item #3 (‘walking or climbing stairs’) 
was excluded from the item candidate pool for Mokken analysis with a lower score than the 
corresponding SAQ item (#4).  
Scale building (Tables 3) 
 Mokken analysis, with a threshold H-value ≥0.50 (“strong” scale), was used to build the 
HeartQoL from the candidate pool of the 26 items.  Mokken analysis identified a bi-dimensional 
instrument with a 10-item physical subscale (H= 0.56) and a 4-item emotional subscale (H =0.54) 
(Table 3).  Without setting an H threshold, the overall HeartQoL questionnaire with all 14 items (H-
value ≥0.50), i.e., the global score, had a uni-dimensional H-value = 0.47 (Table 3 
HeartQoL scores (Table 4)  
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 On a HeartQoL scale response of 0 to 3, higher scores indicate better HRQL.  Mean 
baseline HeartQoL global score in the group as a whole was 2.2 ±0.5; mean global scores were 
highest in patients in patients with MI (2.4 ±0.5), significantly higher (p<0.001) than in patients with 
angina (2.2 ±0.6) that, in turn, were significantly higher (p<0.001) than in patients with heart failure 
(2.1 ±0.6).  A similar pattern by diagnosis was seen in the physical HeartQoL subscale; emotional 
subscale scores were highest in patients with MI but were not different in patients with angina or 
heart failure.  
 
 13
DISCUSSION 
 The HeartQoL questionnaire is a new 14-item IHD-specific core HRQL questionnaire 
based on the items in the SAQ, the MacNew, and the MLHF, with data provided by a cohort of 
6,384 patients living in one of 22 countries with approximately equal numbers of patients with 
angina, MI, or ischemic heart failure.  The HeartQoL appears to have potential as a core IHD-
specific HRQL questionnaire demonstrating that patients with MI have a significantly better HRQL 
than patients with angina who in turn have a significantly better HRQL than patients with heart 
failure.  The evidence for the validity of the HeartQoL questionnaire will be presented in a separate 
manuscript. 
 The 14 items in the HeartQoL scale cluster as a bi-dimensional questionnaire with a 10-
item HeartQoL physical and a 4-item HeartQoL emotional subscale providing a global assessment 
and evaluation of how much a patient with angina, MI, or heart failure perceives he or she is 
bothered by their heart disease.  Conventionally, HRQL consists of at least three domains, a 
physical, an emotional, and a social domain 4.  However, although four MacNew social domain 
items met the clinical impact score inclusion criteria for the 26-item candidate item pool these were 
not included among the 14 items underlying the bi-dimensional latent HRQL HeartQoL construct as 
determined by Mokken analysis.  It appears that that whatever social problems these patients with 
IHD may have, they are not sufficiently unique or strong enough to form an independent latent 
construct.  Alternatively, the MacNew social items may be culture- or diagnosis-specific, and thus 
do not generalize across the three IHD diagnostic groups assessed in this study. 
 There has been global explosion of interest in HRQL instruments as outcomes both in 
clinical practice but also in national and international research endeavors.  We therefore designed 
the HeartQoL Project as an international effort and communicated our interest in conducting the 
project to members of the European Association of Cardiovascular Prevention and Rehabilitation.  
Volunteer investigators from 22 different countries agreed to enroll patients who met the project 
eligibility criteria that, among other factors, required 15 different language versions of the battery of 
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patient-reported questionnaires.  Although the lack of language translations may be considered a 
limitation of the project, accepted linguistic translation techniques such as forward-backward 
translations were used where language versions were unavailable 22.  Although another limitation 
of the project may be the length of time it took to enroll all 6,384 patients, all site investigators were 
volunteers using their own and their staff time and effort to recruit patients. 
 There has been a proliferation of HRQL instruments in the past two or three decades with 
widely varying methods of development, content, breadth of use, and quality principles and 
psychometric property criteria to carry out instrument assessments have been published 27.  
Guidelines for key psychometric attributes of HRQL instruments such as the HeartQoL include the 
conceptual and measurement model, reliability, validity, responsiveness, and respondent and 
administrative burden 27 and these are the focus of a separate manuscript 11. 
 
CONCLUSIONS 
 The HeartQoL questionnaire is a new 14-item, international core IHD-specific assessment 
and evaluation system of the impact of cardiac interventions on patient-reported HRQL that has the 
potential to have an impact on the quality of patient care in the future.  The psychometric properties 
of the HeartQoL questionnaire, with a global score and two subscales, will need to be 
demonstrated before it can be used by clinicians and researchers to a) assess baseline HRQL, b) 
make between-diagnosis comparisons of HRQL, and c) evaluate change in HRQL in patients with 
angina, MI, and heart failure.  
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Table 1. Numbers of patients by region, country within region and by diagnosis 
[angina, myocardial infarction, and heart failure] 
 
Region [sites] Country Diagnosis 
  IHD 
(n) 
Angina 
(n) 
Myocardial 
infarction 
(n) 
Heart 
failure 
(n) 
Total cohort (54) 
 6,384 2,111 2,351 1,922 
Eastern Europe (4) 
 1,307 442 443 422 
 Hungary 330 106 117 107 
 Poland 332 115 112 105 
 Russia 322 110 107 105 
 Ukraine 323 111 107 105 
 
     
Northern Europe (6) 
 1,022 349 362 311 
 Denmark 364 142 117 105 
 Norway 335 105 125 105 
 Sweden 323 102 120 101 
 
     
Southern Europe (13) 
 1,132 366 451 315 
 Italy 327 105 117 105 
 Portugal 354 113 136 105 
 Spain + Cuba 451 148 198 105 
 
     
Western Europe (16) 
 1,449 433 590 426 
 Austria, Germany, 
Switzerland 365 116 143 106 
 Belgium  348 105 137 106 
 France 374 106 159 109 
 Netherlands 362 106 151 105 
 
     
English-speaking (15) 
 1,474 521 505 448 
 Australia 296 77 111 108 
 Canada 352 105 142 105 
 UK + Ireland 357 117 131 109 
 USA 469 222 121 126 
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Table 2. Self-report sociodemographic, risk factors, and Short-form-36 –Version 1 
(SF-36) and Hospital Anxiety and Depression Scale (HADS) mean scores (standard 
deviation) or proportion in the total group and in patients with angina (AP), myocardial 
infarction (MI), or heart failure (HF)  
 
Demographic & risk 
factors 
Total Group 
(n= 6,380) 
AP 
(n= 2,110) 
MI 
(n= 2,350) 
HF 
(n= 1,920) p-value * 
Age (years) 62.5 (11.3) 63.1 (10.2) 59.7 (11.4) 65.1 (11.5) <0.001a,b,c 
Male  75.2% 72.4% 75.9% 77.2% <0.001a,c 
Hypertension ¶  55.5% 63.9% 50.0% 52.7% <0.001a,c 
Diabetes ¶  20.9% 22.7% 15.4% 25.7% <0.001a,b 
Hypercholesterol ¶  59.5% 67.2% 57.7% 53.1% <0.001a,c 
Smoking 15.1% 13.3% 16.7% 15.1% <0.01a,c 
BMI   27.4 (5.0) 28.0 (5.0) 26.9 (4.7) 27.3 (5.3) <0.001a,c 
Physical inactivity ¶¶  69.9% 69.8% 65.4% 75.8% <0.001b,c 
Questionnaires 
     
SF-36  
     
PCS  39.1 (10.3)  37.9 (9.8) 43.1 (9.7) 35.5 (10.0) <0.001a,b,c 
MCS 47.1 (11.0) 46.8 (11.0) 47.4 (10.9) 47.1 (11.2) = 0.17 
HADS 
     
Anxiety  6.3 (4.1) 6.8 (4.0) 5.8 (4.1) 6.3 (4.2) <0.001a,b,c 
% anxious § 34.6% 30.4% 38.6% 35.2% <0.001a,b,c 
Depression  5.1 (3.8) 5.3 (3.7) 4.4 (3.7) 5.8 (3.9) <0.001a,b,c 
% depressed § 25.1% 25.7% 19.2% 31.8% <0.001a,b,c 
 
* p-value between-diagnosis with ANOVA (post-hoc Bonferroni correction; with non-homogeneous 
variances, Welch’s F-statistic and post-hoc Games Howell correction) and Chi-square for 
proportions 
a, MI vs. AP; b, MI vs. HF; c, AP vs. HF 
¶   As told by his/her physician; 
¶¶  Active on <3 occasions per week 
§  HADS score >7 
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Table 3. Candidate item pool (n=26) from the Seattle Angina, MacNew, Minnesota 
Living with Heart Failure questionnaires and the items (n=14) included in the HeartQoL 
questionnaire (physical and emotional subscales); % (proportion bothered); bother score 
(mean); CIS ≥1.00 [clinical impact score; % * bother); H-values bi (bi-dimensional subscales) 
and uni (uni-dimensional scale) 
 
Candidate Pool Items % Bother 
score 
CIS 
≥1.00 
H-value 
bi  
H-value 
uni 
Physical subscale 
   
0.56 --  
Lift, move heavy objects, e.g., furniture, 
children * 69.4 3.2 2.2 0.55 0.49 
Sports/exercise limited ‡ 69.9 2.9 2.0 0.52 0.47 
Tired, fatigued, low on energy ¶ 70.2 2.7 1.9 0.56 0.55 
Walking > a block at a brisk pace * 57.7 2.9 1.7 0.60 0.52 
Physically restricted ‡ 62.3 2.6 1.6 0.53 0.49 
Climb, flight stairs without stopping * 58.5 2.7 1.6 0.58 0.51 
Short of breath ¶ 54.0 2.9 1.6 0.53 0.48 
Garden, carry groceries * 51.8 2.6 1.3 0.62 0.54 
House or yard work difficult ¶ 38.9 2.8 1.1 0.59 0.52 
Walk indoors on level ** 11.7 2.2 0.26 0.52 0.46 
Emotional subscale 
   
0.54 -- 
Worry ¶ 49.9 2.7 1.3 0.57 0.42 
Not relaxed ‡ 55.5 2.3 1.3 0.52 0.36 
Frustrated ‡ 48.8 2.6 1.3 0.51 0.38 
Feel depressed ¶ 40.0 2.6 1.0 0.58 0.42 
H-value for uni-dimensional scale 
  
 -- 0.47 
Items >1.0 but not included 
  
 
  
Worn out ‡ 64.8 2.6 1.7   
Sex ‡ 44.7 3.2 1.4   
Sit or lie down ¶ 54.1 2.6 1.4   
Sleeping well at night difficult ¶ 47.0 3.0 1.4   
Restricted or limited ‡ 58.0 2.4 1.4   
Unsure about exercise ‡ 55.7 2.5 1.4   
Aching legs‡ 52.8 2.6 1.4   
Chest pain ‡ 50.9 2.5 1.3   
Confident ‡ 49.3 2.5 1.3   
Difficult to concentrate, remember ¶ 41.6 2.7 1.1   
Happy with personal life ‡ 44.2 2.4 1.1   
Dizzy/lightheaded ‡ 45.5 2.3 1.0   
* Seattle Angina item;  ** Seattle Angina item included as an activity most patients were not 
bothered by; ‡  MacNew item; ¶  Minnesota Living with Heart Failure item 
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Table 4. HeartQoL health-related quality of life questionnaire mean (± standard 
deviation) scores in the total group and in patients with angina, myocardial infarction (MI), 
or heart failure 
 
 
 
HeartQoL 
Total Group 
(n=6,384) 
Angina 
(n=2,111) 
MI 
(n=2,351) 
Heart 
failure 
(n=1,922) 
p-value *  
Physical score 
 
2.2 (0.7) 2.2 (0.6) 2.4 (0.6) 2.0 (0.7) <0.001 a,b,c 
Emotional score 
 
2.4 (0.6) 2.3 (0.6) 2.4 (0.6) 2.3 (0.7) =0.003 a,b 
Global score 
 
2.2 (0.5) 2.2 (0.6) 2.4 (0.5) 2.1 (0.6) <0.001 a,b,c 
 
p-value between diagnosis with ANOVA (post-hoc Bonferroni correction; in case of inhomogeneous 
variances, Welch’s F-statistic and post-hoc Games Howell correction) and with Chi-square for 
proportions 
 
a, AP vs. MI; b, MI vs. HF; c, AP vs. HF 
 
 
 
 
